EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... February 6, 2023 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... January 15, 2022 Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 Load more HOT NEWS Scientists Find Genetic Changes Linked to Cancer in Children Coming together for Zynlonta Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors De qué manera el seguimiento de los síntomas mejora la atención...
